The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

The latest plain language summary of publication from Neurodegenerative Disease Management describes the findings from an international committee of 10 MS experts who developed recommendations to answer questions about COVID-19 vaccines in people with MS taking cladribine tablets.

Read the full article here.

The original article on which this summary is based is called ‘Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice’ and was originally published in the journal Therapeutic Advances in Neurological Disorders. The original article can be read here.